No Data
No Data
COMPASS Pathways' Stock Sinks To US$3.06, But Insiders Sold Even Lower
Compass Pathways Announces Published Study on Psilocybin in Depression
Express News | Compass Pathways PLC - Comp360 Generally Well Tolerated With Three Reported Tesaes
Express News | Compass Pathways PLC: Top-Line 6-Week Comp005 Data Is Expected in Q2 2025
Express News | Compass Pathways Announces Publication of Results From Comp004 Study on Comp360 Psilocybin for Treatment-Resistant Depression
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup